^
Association details:
| Biomarker: | CCND1 amplification |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).
Published date:
05/16/2018
Excerpt:
Palbociclib and cetuximab resulted in a robust tumor response rate and prolongation of PFS and OS in platinum-resistant HPV (-) RM-HNSCC. The median OS of 12.1 months is the longest reported for patients with platinum-resistant RM HNSCC.
Trial ID:
